Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An expanded access trial of Cabozantinib

Trial Profile

An expanded access trial of Cabozantinib

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 15 Oct 2018 New trial record
    • 08 Oct 2018 According to an Exelixis media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top